AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31873085 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary levels of MMP9, NGAL, CXCL8, and IL-1β
Number of subjects: 17
Study 30124585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (titrated to 200 mg/d)
Number of subjects: 150
Study 30124585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 27585503 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 1305
Study 27585503 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Graft (CABG)
Number of subjects: 1305
Study 25217073 — intervention group
Group type: EXPERIMENTAL
Intervention: senofilcon A (Acuvue Oasys)
Number of subjects: 54
Study 25217073 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon A (Air Optix)
Number of subjects: 54
Study 25217073 — intervention group
Group type: EXPERIMENTAL
Intervention: balafilcon A (Purevision)
Number of subjects: 54
Study 22145959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 459
Study 19796716 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablets providing elemental calcium at 63 mg/day
Number of subjects: 80
Study 19796716 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablets providing elemental calcium at 354 mg/day
Number of subjects: 80
Study 19796716 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablets providing elemental calcium at 660 mg/day
Number of subjects: 80
Study 19796716 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablets providing elemental calcium at 966 mg/day
Number of subjects: 80
Study 17460023 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis (6 mg/kg for 3 weeks, administered orally when enteral feeding achieved)
Number of subjects: 110
Study 17460023 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 110
Study 15659584 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-prevention curriculum
Number of subjects: 279
Study 15659584 — intervention group
Group type: COMPARATOR
Intervention: Health maintenance curriculum
Number of subjects: 279
Study 11837732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 0
Study 11837732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 0
Study 11837732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10361177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving pancreaticoduodenectomy (PPPD)
Number of subjects: 31
Study 10361177 — intervention group
Group type: COMPARATOR
Intervention: Whipple procedure
Number of subjects: 31
Study 10361177 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both procedures
Number of subjects: 31
Study 8832526 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy including prednisone plus interferon (3 Mu/day induction, 3 Mu three times a week maintenance)
Number of subjects: 33
Study 8832526 — intervention group
Group type: COMPARATOR
Intervention: Prednisone therapy
Number of subjects: 33
Study 2076622 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen gel (10%)
Number of subjects: 120
Study 2076622 — intervention group
Group type: COMPARATOR
Intervention: placebo gel (base alone)
Number of subjects: 120
Study 6243531 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cephaloridine
Number of subjects: 300
Study 6243531 — intervention group
Group type: COMPARATOR
Intervention: Polybactrin aerosol
Number of subjects: 300
Study 31204532 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood group O
Number of subjects: 600
Study 31204532 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood group O with family history of DM
Number of subjects: 600
Study 31204532 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood group O without family history of DM
Number of subjects: 600
Study 31621150 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tofacitinib (TOFA)
Number of subjects: 9
Study 30077185 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg subcutaneously every 4 weeks
Number of subjects: 0
Study 30077185 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg subcutaneously every 8 weeks
Number of subjects: 0
Study 30077185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26747850 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation drug-eluting stents (DES)
Number of subjects: 10449
Study 26747850 — intervention group
Group type: COMPARATOR
Intervention: Early-generation drug-eluting stents (DES)
Number of subjects: 10449
Study 24077383 — intervention group
Group type: EXPERIMENTAL
Intervention: PPDC
Number of subjects: 9
Study 24077383 — intervention group
Group type: COMPARATOR
Intervention: CONT
Number of subjects: 9
Study 21538537 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (extended-release) at doses of 50-300 mg/day
Number of subjects: 100
Study 21538537 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine IR (immediate-release) at doses of 25-300 mg/day
Number of subjects: 100
Study 21538537 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 100
Study 21538537 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine IR
Number of subjects: 100
Study 21538537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study 19279424 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.2 percent glyceryl trinitrate (GTN) ointment
Number of subjects: 69
Study 19279424 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 69
Study 17258439 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Nigrovic rule (Meningitest) applied to internal validation set
Number of subjects: 168
Study 17258439 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Nigrovic rule (Meningitest) applied to derivation set
Number of subjects: 168
Study 15237013 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine depletion procedure followed by myomectomy (group II)
Number of subjects: 486
Study 15237013 — intervention group
Group type: COMPARATOR
Intervention: Myomectomy only (group I)
Number of subjects: 486
Study 11881906 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 0
Study 11881906 — intervention group
Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 0
Study 11881906 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing speed and working memory measures
Number of subjects: 0
Study 10367032 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 microgram/day)
Number of subjects: 145
Study 10367032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 10367032 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 145
Study 7547096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium 120 mg
Number of subjects: 23
Study 7547096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2262646 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.2 mg, four times a day) and inhaled beclomethasone dipropionate (BDP, 0.5 mg, four times a day)
Number of subjects: 25
Study 2262646 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (0.2 mg, four times a day)
Number of subjects: 25
Study 445785 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 60
Study 445785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30670158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (elimination of 1 hour of sleep relative to the baseline habitual sleep duration)
Number of subjects: 93
Study 30670158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (exposure to a lamp with no known therapeutic effect)
Number of subjects: 93
Study 30670158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Number of subjects: 93
Study 30670158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 29158665 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of MB12066 (10, 30, 100, 150, 200, 300, or 400 mg)
Number of subjects: 0
Study 29158665 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of MB12066 (100 or 200 mg)
Number of subjects: 0
Study 29158665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25899215 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-to-knee graduated compression stockings (n = 17)
Number of subjects: 34
Study 25899215 — intervention group
Group type: COMPARATOR
Intervention: Conventional socks (control group, n = 17)
Number of subjects: 34
Study 24074269 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention consisting of weekly group participation for six months on nutrition, physical activity, and lifestyle changes, followed by monthly group participation for an additional six months and individual monthly contacts from facilitators during the second six-month phase.
Number of subjects: 200
Study 24074269 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 21415230 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and exercise plus true acupuncture (AE+TA)
Number of subjects: 352
Study 21415230 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and exercise plus nonpenetrating acupuncture (AE+NPA)
Number of subjects: 352
Study 21415230 — intervention group
Group type: COMPARATOR
Intervention: Advice and exercise (AE)
Number of subjects: 352
Study 19152918 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption with audio-visual perturbations
Number of subjects: 14
Study 19152918 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilometric platform measurements
Number of subjects: 14
Study 16539754 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 50
Study 16539754 — intervention group
Group type: COMPARATOR
Intervention: Online tutorial (self-training)
Number of subjects: 50
Study 10390399 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ), 250 mg/d (Maintenance group)
Number of subjects: 23
Study 10390399 — intervention group
Group type: COMPARATOR
Intervention: No CQ (Observation group)
Number of subjects: 23
Study 8720650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation
Number of subjects: 0
Study 8720650 — intervention group
Group type: COMPARATOR
Intervention: Traditional adversarial methods
Number of subjects: 0
Study 1991440 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 1200 mg
Number of subjects: 30
Study 1991440 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 600 mg
Number of subjects: 30
Study 1991440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6341338 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ppm nitrogen dioxide (NO2) for 1 hour
Number of subjects: 30
Study 6341338 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 30
Study 31046880 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Diabetes Self-Management Education (DSME)
Number of subjects: 211
Study 31046880 — intervention group
Group type: COMPARATOR
Intervention: Standard Diabetes Self-Management Education (DSME)
Number of subjects: 211
Study 29510792 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZT)
Number of subjects: 13
Study 29510792 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZT) plus CPAP
Number of subjects: 13
Study 29510792 — intervention group
Group type: COMPARATOR
Intervention: CPAP alone
Number of subjects: 13
Study 29510792 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms (AZT, CPAP, AZT plus CPAP)
Number of subjects: 13
Study 26537156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) every 16 weeks
Number of subjects: 48
Study 26537156 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab every 4 weeks
Number of subjects: 48
Study 24576868 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with subsequent 1-h running at 65% V˙O2max (MOD)
Number of subjects: 9
Study 24576868 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoenergetic intermittent walking at approximately 25% V˙O2max (LOW)
Number of subjects: 9
Study 24576868 — intervention group
Group type: COMPARATOR
Intervention: Prolonged sitting nonexercise control (CON)
Number of subjects: 9
Study 22894725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator FEV₁
Number of subjects: 4484
Study 22894725 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-bronchodilator FEV₁
Number of subjects: 4484
Study 19909301 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical matricectomy with 10% sodium hydroxide
Number of subjects: 30
Study 19909301 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without diabetes)
Number of subjects: 30
Study 17662571 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (200, 300, or 400 mg daily)
Number of subjects: 220
Study 17662571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 17662571 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (up to 400 mg/day)
Number of subjects: 220
Study 15764621 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge rehabilitation service (EDRS)
Number of subjects: 0
Study 15764621 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 12200905 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation for 6 months
Number of subjects: 48
Study 12200905 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 48
Study 10220625 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg TNK-tPA
Number of subjects: 3235
Study 10220625 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg TNK-tPA
Number of subjects: 3235
Study 10220625 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg TNK-tPA
Number of subjects: 3235
Study 10220625 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (30 to 50 mg TNK-tPA)
Number of subjects: 3235
Study 10220625 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated within 6 hours after symptom onset (30 mg TNK-tPA)
Number of subjects: 3235
Study 10220625 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated within 6 hours after symptom onset (40 mg TNK-tPA)
Number of subjects: 3235
Study 7603415 — intervention group
Group type: EXPERIMENTAL
Intervention: Active application (AA) using two PEBA cones fixed bilaterally at point 7 heart
Number of subjects: 6
Study 7603415 — intervention group
Group type: COMPARATOR
Intervention: Placebo application (AP) using two PEBA cones fixed on the back of hand
Number of subjects: 6
Study 7603415 — intervention group
Group type: EXPERIMENTAL
Intervention: Active application (AA)
Number of subjects: 6
Study 7603415 — intervention group
Group type: COMPARATOR
Intervention: Placebo application (AP)
Number of subjects: 6
Study 31198974 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocapnic hyperpnoea training (15-20 min per day, 5 times a week for 4 weeks)
Number of subjects: 18
Study 31198974 — intervention group
Group type: COMPARATOR
Intervention: Control group (no respiratory muscle training)
Number of subjects: 18
Study 29166552 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg/day
Number of subjects: 40
Study 29166552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25384080 — intervention group
Group type: COMPARATOR
Intervention: High-dose oxytocin (6 mU/min with increments every 45 min)
Number of subjects: 200
Study 25384080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose oxytocin (3 mU/min with increments every 45 min)
Number of subjects: 200
Study 25384080 — intervention group
Group type: COMPARATOR
Intervention: High-dose oxytocin (6 mU/min with increments every 45 min) in nulliparous women
Number of subjects: 200
Study 25384080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose oxytocin (3 mU/min with increments every 45 min) in nulliparous women
Number of subjects: 200
Study 25384080 — intervention group
Group type: COMPARATOR
Intervention: High-dose oxytocin (6 mU/min with increments every 45 min) in multiparous women
Number of subjects: 200
Study 25384080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose oxytocin (3 mU/min with increments every 45 min) in multiparous women
Number of subjects: 200
Study 21884018 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated infusion of streptokinase (1.5 MU/20 min)
Number of subjects: 300
Study 21884018 — intervention group
Group type: COMPARATOR
Intervention: Conventional infusion of streptokinase (1.5 MU/60 min)
Number of subjects: 300
Study 21531674 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation practice
Number of subjects: 49
Study 19546253 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured re-assessment system at 6 months post-stroke
Number of subjects: 265
Study 19546253 — intervention group
Group type: COMPARATOR
Intervention: Existing care
Number of subjects: 265
Study 17310863 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg per day of mirtazapine
Number of subjects: 12
Study 17310863 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg per day of mirtazapine
Number of subjects: 12
Study 17310863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15699486 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD3 monoclonal antibody (hOKT3gamma1(Ala‐Ala))
Number of subjects: 0
Study 11341251 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to visual disturbance (flicker, glare, and eyestrain) induced by a very bright, stroboscopic light for varying durations
Number of subjects: 110
Study 11341251 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer exposure to the visual disturbance stimulus
Number of subjects: 110
Study 11341251 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinical advice to avoid headache triggers
Number of subjects: 110
Study 9875725 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 0
Study 9875725 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (serotonin-2A antagonist)
Number of subjects: 0
Study 9875725 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (atypical antipsychotic)
Number of subjects: 0
Study 9875725 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (dopamine antagonist, typical antipsychotic)
Number of subjects: 0
Study 7978432 — intervention group
Group type: EXPERIMENTAL
Intervention: IV propofol (1-2 mg/kg) followed by a propofol infusion (75-100 micrograms.kg-1.min-1)
Number of subjects: 58
Study 7978432 — intervention group
Group type: COMPARATOR
Intervention: IV thiopental (1-3 mg/kg) followed by a pentobarbital bolus (2-3 mg/kg)
Number of subjects: 58
Study 7978432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of anesthesia services for propofol
Number of subjects: 58
Study 7978432 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient morbidity and technical quality of MRI scans
Number of subjects: 58
Study 2558622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine (100 mg/day)
Number of subjects: 72
Study 2558622 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 72
Study 2558622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine-enalapril combination (100 mg/day cicletanine + 20 mg/day enalapril)
Number of subjects: 72
Study 2558622 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 72
Study 1251236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic positioning of nasogastric tubes
Number of subjects: 6
Study 1251236 — intervention group
Group type: COMPARATOR
Intervention: Blind placement of nasogastric tubes
Number of subjects: 6
Study 30422227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab and Radiotherapy
Number of subjects: 0
Study 30422227 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28421669 — intervention group
Group type: EXPERIMENTAL
Intervention: Harsh group
Number of subjects: 0
Study 28421669 — intervention group
Group type: COMPARATOR
Intervention: Neutral group
Number of subjects: 0
Study 28421669 — intervention group
Group type: COMPARATOR
Intervention: Kind group
Number of subjects: 0
Study 25279797 — intervention group
Group type: EXPERIMENTAL
Intervention: DIY whitening (strawberry and baking soda mix)
Number of subjects: 120
Study 25279797 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional whitening modalities (over-the-counter, dentist-dispensed for home use, and in-office whitening)
Number of subjects: 120
Study 25279797 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 120
Study 25279797 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 120
Study 23510505 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence based care following admission to specialist wound clinics
Number of subjects: 70
Study 23510505 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to wound management expertise
Number of subjects: 70
Study 21216851 — intervention group
Group type: COMPARATOR
Intervention: PRED+SAL
Number of subjects: 8
Study 21216851 — intervention group
Group type: EXPERIMENTAL
Intervention: PRED+EXE
Number of subjects: 8
Study 18642654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated CyberKnife stereotactic radiosurgery (CKSRS) with a marginal dose of 1800-2000 cGy/3 fractions, 80 to 89% isodose line (mean 83%), mean 97.9% tumor coverage.
Number of subjects: 21
Study 17135615 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exercise group (40 minutes per day of aerobic exercise)
Number of subjects: 100
Study 17135615 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exercise group (20 minutes per day of aerobic exercise)
Number of subjects: 100
Study 17135615 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exercise group
Number of subjects: 100
Study 17135615 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 17135615 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100